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Highlights 
 BMP signaling is a core signaling cascade in endothelium during vascular
development and homeostasis
 Unbalanced BMP signaling is causative for several vascular dysfunctions
 BMP signaling is highly context-dependent in the vasculature
 Signaling interplay between BMPs and Notch, WNT, and Hippo signaling cascades
co-regulates endothelial cell biology
 BMP signaling is implicated in interpretation of mechanosensitive responses derived
from blood flow
 BMP and anti-BMP treatments are progressively been considered for the treatment of
vascular disorders
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Abstract 
The vascular system is critical for developmental growth, tissue homeostasis and repair but 
also for tumor development. Bone morphogenetic protein (BMP) signaling has recently 
emerged as a fundamental pathway of the endothelium by regulating cardiovascular and 
lymphatic development and by being causative for several vascular dysfunctions. Two 
vascular disorders have been directly linked to impaired BMP signaling, pulmonary arterial 
hypertension and hereditary hemorrhagic telangiectasia. Endothelial BMP signaling critically 
depends on the cellular context, which includes amongst others vascular heterogeneity, 
exposure to flow, and the intertwining with other signaling cascades (Notch, WNT, Hippo 
and hypoxia). The purpose of this review is to highlight the most recent findings illustrating 
the clear need for reconsidering the role of BMPs in vascular biology. 
Keywords: Bone morphogenetic proteins (BMP); Signaling; Vasculature; Development; 
Disease 
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1. Introduction
The vascular system is critical for developmental growth as well as for tissue homeostasis and 
repair. It allows an adequate supply of oxygen and nutrients, removal of waste products, and 
transports liquid and cells through blood and lymphatic vessels. These vessels consist of 
endothelial cells (ECs) lining the interior surface, which – depending on the vessel type - are 
covered by pericytes or vascular smooth muscle cells (VSMCs). The vasculature is constantly 
adapting to meet demands from tissues, which undergo growth, repair or regression. During 
embryonic development, vessel formation first depends on vasculogenesis, which refers to the 
de novo formation of blood vessels from locally differentiating ECs. Subsequently, 
angiogenesis or lymphangiogenesis produces new blood vessels or lymphatic vessels from 
pre-existing ones; all these processes can also occur during adult life. Vascular development 
via sprouting angiogenesis and vascular pruning requires the integration of multiple signaling 
cascades, including vascular endothelial growth factor (VEGF), Notch/Dll4 (delta-like protein 
4) and the TGFβ (transforming growth factor)/BMP (Bone morphogenetic protein) pathways
[1, 2]. 
An extensive review has recently been dedicated on the role of BMP signaling in 
cardiovascular disease [3]. In this review, we discuss the role of the different BMP subgroups 
in angiogenesis, lymphangiogenesis, cardiovascular development, and their function in 
vascular diseases. In addition, the intertwining between BMPs and other signaling pathways 
that impact vascular biology will be highlighted. We will conclude by asking pertinent 
questions in this emerging field e.g. on how mutations in the same pathway can result in 
different diseases in different vascular beds, and how non-SMAD versus SMAD pathways or 
BMP9/10 contribute to endothelial heterogeneity.  
2. BMP signaling
The BMP family consists of about 20 ligands, which are subdivided into at least four groups 
based on sequence similarity, and affinities for specific receptors [4]; the BMP2/4 subgroup; 
the BMP5-7 subgroup; the BMP9/10 subgroup and the GDF5-7 (growth and differentiation 
factor) subgroup. The different subgroups have been implicated in vascular biology, with 
BMP signaling in the endothelium being triggered mostly by BMP2/4/6/9/10 [5]. BMPs are 
secreted dimeric ligands that signal via binding to heteromeric combinations of type 1 [ALK1 
(also known as SKR3), ALK2 (ACTRIA), ALK3 (BMPRIA) and ALK6 (BMPRIB)] and type 
2 (BMPRII, ActRIIA, ActRIIB) transmembrane serine/threonine kinase type receptors (Fig. 
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1) [6]. BMP-receptor binding triggers phosphorylation of the receptor-regulated SMAD1, -5
and -8, in their C-terminal segment. Once phosphorylated these SMADs form hetero-
oligomeric complexes with SMAD4 that bind to DNA together with other transcription 
factors, initiating the SMAD pathway (Fig. 1).  In pulmonary and some other ECs, BMPs also 
activate SMAD2 though less potently [7]. Furthermore, in epithelial cells, mixed complexes 
of pSMAD2 and pSMAD1 have been reported which can activate different sets of target 
genes [8]. Whether or not this is valid in ECs has not yet been documented. BMPs can trigger 
non-SMAD-signaling pathways involving different MAPK kinases (ERK, p38 and JNK), PI3 
kinase/AKT, PKC and others [9] (Fig. 1).  BMP signaling can be modulated by co-receptors 
such as Endoglin, which is strongly expressed on ECs [10], and agonistic or antagonistic 
extracellular proteins such as BMPER (BMP-binding endothelial cell precursor-derived 
regulator), which play an important role in vascular systems [11]. BMPs regulate (Fig. 1) and 
are also regulated by inputs from other pathways that fine-tune BMP signaling activity 
according to context (see section 7, Fig. 4).  
3. BMP signaling subgroups in angiogenesis
3.1.The BMP2/4 subgroup 
Ligands of the BMP2/4 subgroup bind to ALK3 and ALK6 and the corresponding type II 
receptors (BMPRII, ActRIIA or ActRIIB) (Fig. 1) to initiate distinct signaling pathways 
(SMAD or non-SMAD) depending on the mode of receptor oligomerization [12]. While 
SMAD signaling primarily leads to transcriptional regulation of SMAD target genes, non-
SMAD pathways include also direct remodeling of the cytoskeleton or the plasma membrane 
which leads to the polarization and migration of cells [13] or to the induction and/or crosstalk 
regulation of pathways such as MAPK, JNK or PI3K (Fig. 1). Bmp2- and Bmp4-knockout 
mice are early embryonic lethal due to extraembryonic malformations, impaired cardiac 
development, and massive mesoderm defects, respectively [14]. These early and severe 
defects have precluded the analysis of potential vascular phenotypes.  
BMP2 and BMP4 have been described to mediate pro-angiogenic effects both in vitro 
as well as in vivo [15, 16].  There have been contradictory reports regarding the proliferative 
effect of BMP2 in pulmonary arteries versus human umbilical vein ECs (HUVECs) [17, 18]. 
BMP4 was also shown to induce the proliferation of mouse embryonic stem cell (ESC)-
derived endothelial cells (MESECs) and human microvascular endothelial cells (HMECs) 
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[19]. BMP2 and BMP4 both induce migration and tube formation in human microvascular 
ECs and HUVECs [16, 18, 19]. BMP4 promotes the proliferation and migration of ECs via 
stimulation of VEGF-A/VEGFR2 and angiopoietin-1/TIE2 signaling [19]. BMP4, but also 
BMP7 and BMP9, decrease the expression of Apelin in ECs, the ligand for the G protein 
coupled receptor APJ, which is enriched in tips cells [20].  
3.2.The BMP5/6/7 subgroup 
The ligands of the BMP5-7 subgroup can bind to ALK3, ALK6 or ALK2 [12], thereby 
offering a wider range of response (Fig. 1).  Bmp7 deficient mice display kidney failure, and 
defects in skeletogenesis, eye and heart development, and in neurogenesis [21]. However, 
deletion of Bmp5 or Bmp6 is not lethal suggesting that functional compensation by other 
family members takes place, at least in part. These studies did not allow conclusions on their 
potential implication in vascular development. However, interestingly, analysis of 
Bmp6;Bmp7 double mutants showed that BMP6/7 were required for cardiac cushion 
formation [22].  
In vitro, BMP6 induces migration and tube formation in bovine aortic ECs [23]. 
BMP6 induced migration of ECs was shown to be MyoX dependent, and both MyoX and 
ALK6 co-localize in filopodia of polarized cells [24]. Cyclooxygenase-2, which catalyzes the 
conversion of arachidonic acid to prostaglandins, was also shown to play a key role in BMP6-
mediated angiogenesis [25]. A Chip-Seq analysis of SMAD1/5 binding sites in HUVECs 
showed that most of the sites identified with BMP6 overlapped with those of BMP9. The 
target genes include ID1 (Inhibitor of differentiation proteins), HEY1 (hes-related family 
bHLH transcription factor with YPRW motif 1), BMPRII, Endoglin, and JAG1 (Jagged1) 
supporting the notion that these BMPs share some molecular mechanisms in ECs [26].  BMP7 
increased VEGF receptor expression, proliferation and tube formation in ECs [27]. However, 
it was also recently published that a variant form of BMP7 represses tube formation in a 
SMAD4-independent manner, and decreases VEGFR2 and FGR1 expression [28].  
3.3. The BMP9/10 subgroup 
BMP9 and BMP10 bind to the endothelial-specific receptor ALK1 with very high affinity 
(EC50 = 50 pg/mL, 2 pM) [29-31] (Fig. 1). BMP9 can also bind to ALK2 but only in the 
presence of a type II receptor [31], while BMP10 can also bind ALK3 [32]. BMP9 and 
BMP10 bind to the three BMP type II receptors though apparently with different affinities [29, 
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33]. The direct binding of BMP9 and -10 to the co-receptor Endoglin contrasts other TGFß 
family members that require the presence of a type 1 or type 2 receptor for Endoglin binding 
[30, 31, 34, 35]. So, despite apparent sequence homology it is likely that BMP9 and BMP10 
do not always use the same receptor complex.  
The main source of BMP9 and BMP10 are the liver and the heart, respectively [36-38]. The 
onset of Bmp10 expression precedes Bmp9 expression in the mouse (E8.5 versus E9.75–10) 
[39]. BMP9 and BMP10 are present in the circulation (0.5-15 ng/mL [30, 39]). However, 
plasma from Bmp9-knockout mice is not able to activate a BMP-SMAD signaling reporter 
(BRE, BMP Responsive Element [40]) [41], and most of the BRE-activity is inhibited by a 
neutralizing anti-BMP9 antibody [30, 39, 41] suggesting that BMP9 is the bioactive form 
within the circulation.  
The role of ALK1 and Endoglin in vascular development has been clearly 
demonstrated by gene deletion in mice. Both Acvrl1 (ALK1) and Eng deletions lead to 
embryonic lethality due to severe vascular abnormalities, including excessive capillary fusion 
[arteriovenous malformations (AVMs)], hyperdilation of vessels and deficiency of 
differentiation and recruitment of VSMCs [42-45]. Bmp10-deficient mice die between E9.5 
and E10.5, due to cardiac development defects [46], but recently vascular defects in the yolk 
sac and in the embryo have also been found [39]. On the other hand, Bmp9 inactivation 
results in viable mice. Analysis of the retinal vascularization in these mice, as a model of 
physiological angiogenesis, does not show any significant defect [39, 41]. However, injection 
of a neutralizing anti-BMP10 antibody in Bmp9 knockout mice strongly inhibits vascular 
expansion of the retina and induces an increase in vessel density, demonstrating a redundancy 
between these two BMPs in vascular development [39, 41]. Similar results were obtained by 
injecting the extracellular domain of ALK1 (ALK1ECD), which traps all ligands of ALK1 [41, 
47]. BMP9 overproduction inversely inhibits retinal sprouting [47]. Redundancy between 
BMP9 and BMP10 has recently also been shown in the closure of the ductus arteriosus [48]. 
The role of ALK1, BMP9, and BMP-10 in vascular development has been confirmed in the 
zebrafish [49]. Injection of bmp9 morpholinos had no effect on cranial vasculature but 
generated a venous remodeling defect in the tail [50]. On the other hand, bmp10 morphants 
present a phenotype that is indistinguishable from alk1 morphants [51]; arteries are enlarged, 
contain supernumerary ECs and AVMs connect the arterial system underlying the midbrain 
and hindbrain to adjacent veins. Therefore, BMP10, which is expressed first in mice and 
zebrafish, apparently plays a key role during early embryonic development and may control 
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EC numbers in nascent arteries [39, 51]. With the onset of BMP9 synthesis, both BMPs are 
involved in blood vascular development in an interchangeable manner and ensure vascular 
quiescence. Interestingly, this does not seem to account for lymphatic development, as Bmp9 
knockout mice present lymphatic defects [52] (see section 4).  
Although in vivo data clearly indicate major roles for BMP9 and BMP10 in vascular 
remodeling, the cellular mechanisms mediated by BMP9 and BMP10 signaling in ECs are 
still not fully understood. Pro- and anti-angiogenic roles have been proposed for 
BMP9/BMP10 [7, 30, 31, 53-61]. These studies used different ECs, different doses of BMP9 
and different experimental models, which likely explains the observed differences. Ex vivo, 
BMP9 inhibits EC sprouting in the metatarsal culture model and in angiogenic pancreatic islet 
cultures [31, 62] and it inhibits neo-angiogenesis in the sponge assay [63]. Concerning 
cellular mechanisms, BMP9 and BMP10 regulate the expression of many genes involved in 
vascular remodeling. They increase the synthesis of ID1, ID2, SMAD6, SMAD7, ENG, 
BMPRII, Interleukin-8 (IL-8), E-selectin, Endothelin-1, CXCR4 (the SDF1 (stromal-derived 
factor 1) receptor) [7, 30, 53, 55, 56, 64], while they reduce APLN (Apelin) expression [20, 41, 
64]. BMP9 and BMP10 activate the expression of transcription factors (HEY1, HEY2, HES1) 
as well as ligands JAG1 (Jagged1) of the Notch signaling pathway [26, 41, 47, 65-67], but 
also ephrinB2 [56], FGFR1 and 2 [68] and VEGFR1 [47] supporting important crosstalks 
between the BMP signaling pathways and other pathways (see further). Interestingly, BMP9 
also strongly induces the expression of ALK3, ALK6 and BMPR2 allowing ECs to respond to 
other BMPs [55] in a positive feed forward loop as previously proposed [69]. Conversely, 
BMP9 also increases the expression of BMPER, which negatively regulates the activity of 
many BMPs [11, 70] (Fig. 1). 
Altogether, these data show that the circulating BMP9 and BMP10, owing to the 
high expression of their receptors BMPRII, ALK1 and Endoglin in ECs, are two fundamental 
players in vascular development.  Their cellular roles are still not completely understood but 
they are likely to function in a dose- and context-dependent manner within normal and 
dysregulated vascular beds.  Importantly, BMP9 has recently been tested with success in pre-
clinical mouse trials to treat vascular dysfunction like PAH [59] and ischemic 
neovascularization [60] (see section 6.5).  
4. BMPs and lymphangiogenesis
The lymphatic vascular system drains interstitial fluids into the circulation, and regulates fat 
uptake and immune control. It is involved in numerous pathologies such as lymphedema, 
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lymph stasis, inflammatory diseases and tumor metastasis [71]. BMP signaling has recently 
been shown to be essential for lymphatic development in mice and zebrafish. Niessen et al. 
[72] showed that injection of ALK1ECD or of a blocking anti-ALK1 antibody into newborn 
mice disrupted lymphatic development within the tail and intestine. An anti-proliferative role 
of ALK1 in postnatal lymphatic development was proposed because of the presence of 
enlarged lymphatic vessels within the cornea, intestine, and diaphragm of mice with an 
induced deletion of Alk1 [73]. Enlarged lymphatic capillaries and collecting lymphatic vessels 
in mesentery, ear skin and back skin are also present in Bmp9-deficient mice, compatible with 
BMP9 being the ALK1 ligand involved in lymphatic vascular development [52, 73]. 
Furthermore, Bmp9-knockout mice also have a reduced number of lymphatic valves and 
decreased drainage efficiency [52]. Further, adenovirus-mediated overexpression of BMP9 
diminishes inflammatory lymphangiogenesis in mice [73]. In vitro, lymphatic endothelial cell 
(LEC) sprouting is induced by the addition of ALK1ECD, BMPRIIECD, or ACVRIIBECD [72]. 
In accordance with this result, BMP9 and BMP10 inhibit LEC proliferation, migration, and 
tube formation [73, 74]. In LEC, BMP9 inhibits LYVE-1 expression in agreement with a role 
in lymphatic maturation and induces the expression of several genes known to be involved in 
valve formation (Foxc2, Connexin37, EphrinB2 and neuropilin1) [52]. BMP9 also transiently 
inhibits the expression of the lymphatic transcription factor Prox1 [52, 73] and induces 
SMAD6 expression [72]. BMP9 is also proposed to induce the reprograming of LEC to blood 
ECs (BECs) as it inhibits the expression of VEGFR3, Podoplanin, Neuropilin2 expression 
and increases VEGFR2, Endoglin and TIE2 expression [73]. Taken together, these data are in 
support of a role of BMP9 in inhibiting lymphangiogenesis in vitro and in promoting 
lymphatic maturation and valve formation in vivo.  
BMP2 also regulates lymphatic development: Bmp2b overexpression inhibits the 
differentiation of LECs in zebrafish embryos and addition of BMP2 attenuated LEC 
differentiation in mouse embryoid body cultures [75]. Mechanistically, BMP2 promotes the 
expression of miRNAs, including miR-31 and miR-181a, which in turn negatively regulate the 
stability of Prox-1 mRNA [75]. On the other hand, morpholinos against the receptors Alk3, 
Alk3b, Bmpr2a and -b or Smad5 decreased the number of LECs in zebrafish [76]. These 
results are in contrast with the anti-lymphangiogenic effects of BMP2 signaling which also 
signals via Alk3 [75] and suggest that other BMPs can bind to ALK3 and play a pro-
lymphangiogenic role.  
BMPs have also been involved in tumor lymphangiogenesis. BMP9 expression in the 
tumor mammary cell line 4T1 inhibits tumor lymphangiogenesis [73]. In contrast, blockade of 
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ALK1 reduced tumor lymphangiogenesis in the MDA-MB-231 mouse breast cancer cell 
model [77]. Taken together, these results illustrate that - like in the case of blood vessels - 
BMP signaling may modulate development and/or maintenance of lymphatic vessels in a 
context-dependent manner. 
5. BMPs in cardiovascular development
BMPs play well-established roles in the regulation of early heart development and 
morphogenesis (reviewed in [78]). Recent studies, mainly in zebrafish but also in mice, show 
that BMPs also mediate the accommodation of the vasculature to altered hemodynamics and 
vascular remodeling, a new emerging domain for BMP signaling. 
5.1. BMPs in the formation of axial and caudal veins in zebrafish 
In tune with cell culture experiments, striking molecular differences for the roles of BMPs 
were also discovered in the zebrafish vasculature. ECs of the embryonic axial and caudal 
veins require BMP signaling to initiate sprouting morphogenesis, whereas those of the 
neighboring dorsal aorta are not responsive to this molecular cue [79]. These differences in 
sensitivity can be explained by differences in the expression of essential components of BMP 
signaling between both arterial and venous cell types. The higher expression levels of BMP 
type II receptors [79, 80], cargo-adaptor protein Dab2 [80], a factor that is required for the 
propagation of BMP signaling via SMADs [81], and LDL receptor-related protein 1, a 
component of the endocytic machinery required for BMP receptor signaling [82], may make 
venous beds more sensitive to BMPs. Two reviews have covered the main discoveries of 
these studies and, hence, this work will not be further discussed here [83].  
Bmp2b-induced sprouting from the caudal vein was recently shown to be mediated 
through a regulatory cascade involving Arhgef9b, Cdc42, and Formin-like 3, an Actin-
regulatory protein important for filopodia formation [84].  
BMPs also play important roles in the stabilization of caudal vein EC differentiation 
by activating β-catenin-dependent transcriptional activity in a BMP receptor-dependent 
manner, which leads to the transcription of venous-specific genes including nr2f2/coup-tfII, a 
key regulator of caudal vein differentiation in the zebrafish embryo [85]. The activation of β-
catenin by Bmps involves a Bmp-dependent upregulation of Angiogenic factor with G patch 
and FHA domains 1 (aggf1), a chromatin-associated nuclear protein that is required for 
venous specification of ECs in the zebrafish embryo that has been implicated as the causative 
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factor in a human venous endothelial malformation that is part of the Klippel-Trenaunay 
syndrome [86]. Recent studies have implicated miR-26a as a negative regulator of Bmp 
signaling during formation of the zebrafish caudal vein. miR-26a targets Smad1 in ECs and 
the overexpression of miR-26a in zebrafish inhibited caudal vein formation [87].   
However, a number of findings also point at different context-dependent molecular 
and cellular roles for BMP signaling in arteries and veins in mouse and zebrafish. There is 
prominent BMP-SMAD signaling in arteries and veins in the mouse embryo, as indicated by 
nuclear pSMAD1/5/8 expression and activity from a transgenic BRE:GFP reporter [65, 88]. 
Also, the primarily arterial defects observed in mice with endothelial deficiency of Acvrl1/ 
Eng, or with an endothelial-specific double knockout of Smad1;Smad5 contrast with the 
exclusive venous phenotypes upon loss of BMP signaling in the zebrafish. The phenotypes 
observed under these conditions included ectopic sprouting of intersomitic vessels from the 
dorsal aorta [65]. Yet, the different approaches used to interfere with BMP signaling in 
zebrafish and mouse may also contribute to some of the observed differences [89]. Also, the 
role of BMP within arteries might only be very temporal and, hence, a combination of 
sophisticated inducible cell-type specific gain- and loss-of-function approaches and their 
crucial rescue experiments are required to resolve this issue.  
5.2. BMPs and the endocardium 
The endocardium is a specialized endothelial bed that is lining the interior of the myocardium. 
Studies in the mouse demonstrate that myocardial expression of BMPs (reviewed in [78, 90, 
91]), and especially BMP2 [91-93], are critical for induction of endocardial cushion 
differentiation and endothelial-to-mesenchymal transition (EndMT) in the atrioventricular 
canal, which precedes valve formation. BMP4 is also required for endocardial cell 
proliferation in the outflow tract [94] while compound mutants for Bmp6/7 show distinct 
valvulogenesis defects [22].  
Recent studies in zebrafish confirm that BMP signaling plays also important roles in 
early endocardial morphogenesis and differentiation [95, 96]. During cardiac ballooning, 
when the two cardiac chambers of zebrafish approximately double to triple in volume, the 
inhibition of BMP signaling almost completely blocks endocardial cell proliferation [95]. The 
myocardium is a rich source of BMPs (reviewed in [78]) and among the BMPs that are 
expressed within the myocardium are BMP 2/4/5/6/7/10/16 [97, 98]. While the activity of 
BMP signaling is dampened within the myocardium (in the early zebrafish this is in part due 
13 
to the strong activation of inhibitory Smad6a [99]), endocardial cells in zebrafish and mouse 
strongly express the BMP receptor genes alk3/6/8 and alk2/6 respectively, and are highly 
responsive to BMPs as indicated by high levels of nuclear pSMAD-1/5/8 [78, 95]. In mouse, 
ectopic production of Noggin within the cushion endocardium only, results in undersized 
bradycardic hearts with immature cardiomyocyte contractile apparatus, hypoplastic 
endocardial cushions and altered expression profiles of Alk1/Endoglin and BMP/TGFβ 
effectors [100]. In line with this is the observation that BMPER and Smad6 dampen the BMP-
SMAD pathway in cardiac cushions to control cushion mesenchyme thickness [101, 102]. 
This illustrates that balanced levels of BMP activity are necessary for endocardial-
cardiomyocyte crosstalk, and that suppression of BMP signaling results in both heart valve 
and myocardial trabeculae defects.  
Depletion of myocardial cells in zebrafish by chemical inhibition using the 
genetically-encoded nitroreductase system prevents normal endocardial differentiation as 
indicated by the lack of expression of the endocardial-specific marker gene nfatc1 [96]. The 
endocardial phenotype was rescued by expression of Bmp2b, which complemented the lack of 
myocardium and restored the expression of nfatc1. Hence, myocardium-derived Bmp2/4 
signaling is pivotal for endocardial proliferation and differentiation.  
5.3. BMP signaling and blood flow responses 
Intriguingly, endocardial proliferation during these developmental stages was also triggered 
by the mechanical stimulus of blood flow [95]. Hemodynamic alterations induced by shear 
stress are sensed in the endothelium by PECAM/VE-cadherin/VEGFR2, proteoglycans 
embedded in the glycocalyx, the primary cilium and ion channels and are transmitted into 
biochemical signaling cues. Crosstalk between biomechanical and BMP signaling has been 
described before in several cell systems including osteoblasts and ECs [51, 103-105]. 
However the molecular mechanisms of how distinct mechanosensitive target genes are 
regulated synergistically with the BMP pathway in the vasculature are still largely unclear.  
In particular the fraction of retrograde flow is a hemodynamic parameter with a strong 
impact on endocardial cell proliferation. These observations support the involvement of BMP 
signaling in mechanosensitive responses to blood flow and circulatory BMP ligands. One 
example is the BMP receptor ALK1, which is activated in response to blood flow [106, 107] 
(Fig. 2). Conversely, the occlusion of blood vessels or a lack of blood flow will result in the 
activation of angiogenesis or adaptive arteriogenesis in the adult. In zebrafish, blood flow 
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promotes Alk1 activity by concomitantly inducing alk1 expression and distributing Bmp10, 
thereby reinforcing this pathway, which is proposed to limit arterial caliber at the onset of 
flow [51].  
Altered hemodynamics in the adult aortic valve leaflets in mice upregulate the levels 
of the endothelial adhesion molecules ICAM-1 and VCAM-1 in a BMP4-dependent manner 
[108], while transient and persistent SMAD1/5/8 phosphorylation was reported upon 
exposure of endothelium to laminar shear stress (LSS) or oscillatory shear stress (OSS), 
respectively [104] (Fig. 2). Remarkably, the pro-inflammatory role of BMP4 was only shown 
for the ligand in systemic but not in pulmonary circulation [109]. BMP2, in contrast to BMP4, 
was not shown to be shear stress responsive, yet, it also elicits pro-inflammatory responses 
[110]. Force-specific activation of SMAD1/5 has been reported to cause endothelial 
proliferation in stenosed rat aorta, which involves BMP receptor-integrin interactions (ALK6-
αvβ3) [111]. This pathway subsequently activates Runx2/mTOR/p70S6K pathways that 
regulate the cell cycle [111] (Fig. 2). The authors concluded that BMP-SMAD activation 
occurred ligand-independently because overexpression of the BMP-antagonist Noggin could 
not rescue the effect; however such an approach would not rule out the involvement of 
BMP9/10 and ALK1-mediated activation of SMAD1/5 because BMP9/10 are Noggin 
insensitive [63]. Recently, MSX1 was identified in mice as an arterial-specific transcriptional 
mediator of SMAD1/5 dependent transduction of extrinsic arterial shear after femoral artery 
ligation. MSX1 induces an inflammation-mediated vascular remodeling response by direct 
induction and production of ICAM-1 and VCAM-1 [112] (Fig. 2). 
Flow is reported to regulate cilia in ECs, with cilia being present when flow is low and 
disturbed, while being absent in regions with high shear stress [113]. Flow-induced loss of 
cilium sensitizes the endothelium for EndMT in cardiac valve forming regions in the 
embryo. Moreover, lack of primary cilium sensitizes ECs for BMP-induced 
mineralization in the adult vessel wall in atherosclerotic plaques [113, 114]. The primary 
cilium in ECs is thought to arrest the cells in a quiescent stage by controlling β-catenin 
availability. The lack or the disruption of the primary cilium leads to nuclear accumulation of 
β-catenin and activation of expression of Slug (Fig. 2). BMP-SMAD signaling potentiates 
expression of Slug in a β-catenin-dependent manner, thereby contributing to the 
atherosclerotic calcification of ECs [114]. Whether pSMAD1/5 triggers potentiation of β-
catenin through aggf1, like in venous identity specification [85], has remained unaddressed. 
Recently, it was shown that BMP6, but not BMP9, synergizes with pro-atherogenic oxidized 
low-density-lipoproteins on transcription of different osteogenic and chondrogenic proteins in 
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human aortic ECs [115], linking BMP signaling and oxidative stress, and the above described 
flow and inflammation in recruiting vascular calcification associated with atherosclerosis. 
6. BMPs in vascular diseases
Disruption of BMP signaling has been associated with the development of various vascular 
disorders and vascular dysfunctions. We will present here the major ones (Fig. 3).  
6.1. Pulmonary Arterial Hypertension 
Pulmonary Arterial Hypertension (PAH) is a rare vascular disorder (25 cases/million) defined 
as an increase in mean pulmonary arterial pressure >25 mmHg at rest [116]. The increase in 
pulmonary vascular resistance is attributable to constriction of small pulmonary arteries 
caused by profound vascular remodeling. Aberrant proliferation and apoptosis resistance of 
ECs, VSMCs and fibroblasts lead to a reduction in the luminal area, increased blood pressure 
and ultimately, death from right ventricular failure. An association between mutations in 
BMPRII (BMPR2), ALK1 (ACVRL1), or more recently SMAD8 (SMAD8) and PAH has been 
described [117-119].  
Several BMP ligands play a key role in pulmonary hypertension. BMP2/4 stimulate 
BMPRII and induce endothelial nitric oxide synthase (eNOS) phosphorylation and activity 
leading to pulmonary artery EC (PAEC) proliferation, survival, and migration. However, in 
the presence of BMPR2 mutations, BMP2/4 cannot induce eNOS expression in ECs, 
contributing to the phenotype of PAH [120]. Recent studies have demonstrated that BMPRII 
forms a signaling complex with ALK1 in EC in response to BMP9 and BMP10 [29-31], 
supporting that this pathway has a central role in the pathophysiology of PAH. BMP9 induces 
BMPRII expression that mediates the IL-8 and E-selectin induction and growth inhibition 
observed in PAECs [7, 30]. Interestingly, PAECs from Bmpr2 (+/-) mice have a 
constitutively activated SRC kinase, an increased numbers of caveolae, and impaired 
endothelial barrier function supporting that non-SMAD signaling pathways are involved 
in the physiopathology of BMP-related vascular diseases [121].  
Sildenafil and prostacyclin analogues are currently used to treat PAH and they were 
shown to partly restore deficient BMP signaling [122, 123]. Sildenafil is a PDE5 
(phosphodiesterase 5) inhibitor, thereby blocking the enzyme for cGMP degradation. Of 
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interest here is that the cGMP kinase (cGKI) was shown to interact with BMPRII and to 
support SMAD-signaling [124] Recently, screening of FDA-approved drugs identified 
tacrolimus, a potent immunosuppressor, which when injected into mice with conditional 
deletion of Bmpr2 prevented the development of PAH [125]. More recently, administration of 
BMP9 in vivo prevented and also reversed established pulmonary hypertension in two rat 
models of PAH, as well as in a new mouse model bearing a knock-in allele of a common 
human disease-causing allele (Bmpr2+/R899X), highlighting the therapeutic potential of BMP9 
as a possible treatment for PAH patients [59].  
6.2. Hereditary Hemorrhagic Telangiectasia 
Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu–Osler–Weber syndrome is a rare 
(1/8000) autosomal dominant disorder characterized by frequent epistaxis, telangiectasia in 
skin and mucosa, and AVMs in lung, liver or brain, and hemorrhages associated with these 
vascular lesions [126]. Mutations in the genes encoding endoglin (ENG), ALK1 (ACVRL1), 
SMAD4 (SMAD4) and more recently BMP9 (GDF2) have been associated with the 
development of HHT or related HHT [127].  
The cellular role of ALK1 is still not completely understood and the most frequent 
hypothesis is that the pathogenesis of HHT could be due to an enhanced response to 
angiogenic cues in ALK1- or Endoglin-deficient ECs [57]. In accordance, therapeutic 
approaches blocking pathological angiogenesis (such as anti-VEGF antibodies or 
thalidomide) have yielded beneficial effects to the patients [128, 129]. In the future, 
administration of BMP9 or BMP10, as for PAH [59], or additional approaches directed to 
stimulate the deficient pathway, could result in an effective therapy for HHT patients 
(discussed in [130]). In this sense, the immunosuppressant sirolimus, when given to an HHT 
patient to prevent liver transplantation rejection, resulted in loss of telangiectases, epistaxes, 
and anemia [131] suggesting that a similar approach for PAH [125] and HHT could 
potentially be intended in the future. 
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6.3. Cerebral cavernous malformation 
Cerebral cavernous malformation (CCM) is a vascular dysplasia, mainly localized within the 
brain. CCM lesions are formed by enlarged and irregular blood vessels that often result in 
cerebral hemorrhages. CCM is caused by loss-of-function mutations in one of three genes, 
namely CCM1, CCM2 and CCM3, and occurs in both sporadic and familial forms [132]. It 
was recently described that EndMT in CCM1-abblated ECs is mediated by upregulation of 
Bmp6 and inhibitors of the TGFß and BMP pathways reduced the numbers and sizes of 
vascular lesions in Ccm1-deficient mice [133].  
6.4. Vascular calcification 
Vascular calcification is a common feature encountered in several pathologies such as 
atherosclerosis, chronic kidney disease, diabetes and hypertension. Vascular calcification is a 
tightly regulated process that involves differentiation of ECs into chondrocyte- and 
osteoblast-like cells followed by mineralization of the surrounding matrix. It was shown that 
BMP2 and -4 s are upregulated in atherosclerotic sites potentiating the calcification [134, 
135], whereas BMP inhibition by BMP antagonist (matrix Gla protein, MGP) or treatment 
with pharmacological inhibitors of BMP signaling reduces vascular inflammation and 
calcification [136]. In this sense, overexpression of MGP is shown to attenuate vascular 
calcification in ApoE-/- mice [137, 138]. Another study showed that treatment with LDN-
193189, a small molecule BMPRI kinase inhibitor, or ALK3ECD led to reduction of vascular 
inflammation and calcification in Ldlr-/- mice [139]. A recent study showed that oxidized-
LDL (oxLDL) and BMP6 synergistically recruit osteogenic differentiation in ECs providing a 
potential mechanism for the interactions of BMP signaling, oxidative stress, and inflammation 
in recruiting vascular calcification associated with atherosclerosis [115]. 
6.5. Ischemic neovascularization 
Vasculogenesis and angiogenesis play also a crucial role in adults in various ischemic 
disorders. Several therapeutic approaches are highlighting the potential of using endothelial 
progenitor cells (EPCs) to promote re-endothelialization of damaged vessels and to enhance 
neovascularization after ischemic diseases such as heart and limb ischemia. A very recent 
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report showed that BMP9 in a mouse hindlimb ischemia model enhances blood flow recovery 
in vivo [60]. 
6.7. Tumor angiogenesis 
Angiogenesis plays also a key role in tumor growth, invasion and metastasis. Current anti-
angiogenic therapies in cancer are mainly focusing on targeting VEGF signaling. However, 
the development of anti-VEGF therapy resistance as well as compensatory angiogenic 
mechanisms by the tumors, has urged the search of alternative approaches, including 
modulation of BMP signaling [136]. Altered expression of BMPs has been found in several 
types of cancer (ovarian, gastric, lung, colon, breast) [136]. Among them, BMP2 and -4 have 
been shown to promote tumor angiogenesis via different mechanisms. Blockade by BMP 
antagonists like Noggin or Chordin, or specific antibodies resulted in reduced tube formation 
in a melanoma model, or decreased tumor growth in vivo in a lung carcinoma mouse model 
(reviewed in [136]). 
Since ALK1 and endoglin are specifically expressed on ECs, several studies have 
focused on ALK1 or Endoglin as promising targets to interfere with tumor angiogenesis [10, 
140]. Targeting ALK1 directly by using anti-ALK1 antibodies or by sequestering BMP9 and 
10 with the ligand trap ALK1ECD, has been performed in mouse preclinical models and phase 
2 clinical trials; Two studies published in 2015, using mouse models and ALK1ECD, show 
slightly different results; one shows that ALK1 ECD reduces tumor growth, vessel density and 
metastasis [141] while the other shows no effect on tumor growth but a normalization of the 
vessels and a beneficial effect combining ALK1ECD with cisplatin [142]. The conclusions of 
the first two clinical trials are that blocking ALK1 as a monotherapy is insufficient and that 
combinatory therapy should be investigated [143, 144]. Inhibition of EC proliferation and 
tumor growth has also been achieved in mouse cancer models by targeting Endoglin [10]. 
Injection of EndoglinECD results in inhibition of VEGF-induced angiogenesis and tumor 
growth, highlighting its potential as a therapeutic target in tumor angiogenesis [145, 146].  
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7. BMP signaling interplay in the vasculature
BMP pathways are intensely regulated by inputs from other pathways that fine-tune BMP 
signaling activity according to contextual status (Notch, WNT, Hippo, FGF, VEGF, Ephrins, 
apelin). We will present here the most relevant signaling interplay in the vasculature.  
7.1. BMP and Notch signaling 
Notch signaling is critical to balance angiogenic sprouting by limiting the tip cell and 
promoting the stalk cell phenotype [1](Fig. 4A), to trigger EndMT in endocardium during 
cardiac valve formation and to regulate context dependently LEC specification and lymphatic 
valve formation. In contrast to BMPs, Notch mediated signaling elicits binary types of 
responses. Interaction between membrane-embedded Delta-like (DLL) and Jagged (JAG) 
ligands and the Notch-receptor requires cell-cell contact. The Notch receptor becomes 
proteolytically processed upon ligand-receptor interaction, its intracellular domain (NICD) 
translocates into the nucleus where it complexes with RBP-J and Mastermind to activate 
expression of target genes [147].   
Different interactions between the BMP and Notch cascade have been reported in 
vascular cell types (reviewed in [78, 148]). BMP9 and -6 signaling directly regulate 
expression of JAG1 and HEY2 in ECs through binding of SMAD1/5 to GC-SBE binding sites 
in their promoter [26]. JAG1 dampens DLL4-Notch signaling in tip cells [149]. BMP-
SMADs and SMAD4 can also form a complex with NICD and RBP-J resulting in BMP 
enhanced recruitment of the complex to the RBP-J binding site to transactivate target genes of 
Notch signaling like Hey1/2 and Cdh2 [150, 151] (Fig. 4A).  
Interestingly, several studies indicate that pSMAD1/5/8 can activate Notch target 
genes like Hey-1/2 and Ephb2 in a Notch/RBPJ-independent manner [41, 47, 66, 152]. Loss-
of-function of Notch and/or Alk1 signaling in zebrafish shows that both exhibit context-
specific and target-specific interactions in controlling Notch target gene expression in vivo e.g. 
in the dorsal aorta, but also that AVMs associated with Alk1 deficiency do not result from 
perturbations in Notch activity [152]. This illustrates that care should be given when 
generalizing findings to different vascular beds and setting.  
BMP and Notch signaling seem to synergize and to antagonize each other often in 
the same cell type to dynamically control cellular signaling responses (Fig. 4A). HEY and 
HES1 are basic helix-loop-helix (bHLH) transcriptional repressors, while ID proteins are 
HLH factors that can dimerize with bHLH proteins. The ID-HES1 interaction releases the 
negative autoregulation of HES1, which results in increased expression of Hes1 [153]. 
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However, upon increased production of HEY2, the latter can compete with HES1 for ID-
binding, and HEY2-ID complexes are targeted for proteosomal degradation [65, 150]. 
Relative abundance of HES1, ID and HEY-components may thus pivot BMP and Notch 
signaling modes between synergy and antagonism [148]. 
Reciprocal BMP and Notch signaling between the endocardium and the myocardium 
is required for initiation of EndMT in the valve forming site: with Jag1 being induced in 
endocardium by BMP signaling, while JAG1-Notch1 signaling regulates on its turn Bmp2 
expression in myocardium [92, 154], a process that has extensively been reviewed [78]. 
Recently, Neuropilin 1 (NRP1) has been linked in ECs to Notch and TGFβ signaling 
[155]. NRP1, a transmembrane co-receptor for several unrelated ligands, limits activation of 
SMAD2/3, and perhaps also SMAD1/5/8, through ALK1 and -5. Doing so, NRP1 represses 
actively stalk cell phenotype in the tip cell; while Notch mediated signaling represses Nrp1 in 
the stalk cell. It is yet unclear how NRP1 interferes with phosphorylation of SMAD2/3; 
whether Notch-mediated repression of Nrp1 involves SMADs directly or involves SMAD- 
and Notch-effectors. This work supports a paradigm launched by Moya et al. [65], that the tip 
cell is not the default response, but requires active suppression of the stalk cell phenotype. 
These studies show that cells transfected with siRNAs against ALK1, ALK5, SMAD2/3 or 
SMAD1/5 preferentially occupy the tip position in mosaic HUVEC tip cell competition assays. 
Hence, pSMAD1/5 and now also pSMAD2/3 appear critical for stalk cell competence and 
phenotype, likely prior tip cell selection. Interestingly, deletion of a single copy of Nrp1 
normalizes the hypervascular phenotype observed in Alk1-deficient retinas raising the 
possibility of targeting NRP1 as a therapeutic approach for HHT patients or other vascular 
disorders [155]. 
7.2. BMP and WNT signaling 
WNT signaling pathways play a key role in angiogenesis, cardiac development and disease 
[156]. WNTs are a family of 19 secreted glycoproteins that signal through distinct pathways, 
referred to as the canonical WNT/β-catenin pathway, the non-canonical WNT/calcium and 
the planar cell polarity (PCP) pathways depending on the WNTs acting respectively via 
frizzled (FRZ) receptors, or via a complex composed of FRZ and LRP5/6, or the 
transmembrane receptor tyrosine kinases ROR2 and RYK.  
Reciprocal BMP and Notch signaling is required for EndMT in the valve forming 
site, and regulates Wnt4 expression in the endocardium [154]. Inhibition of WNT signaling, 
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presumably WNT4, in whole embryo mouse cultures has shown that Bmp2 and Msx1 
expression in myocardium depends on WNT signaling; and either BMP2 and WNT4 can 
rescue the defective EndMT resulting from Notch inhibition, with WNT4 rescue requiring 
BMP activity [154]. The BMP/SMAD axis activates directly expression of the T-box 
transcription factor Tbx20 [157], which on its turn regulates the WNT pathway to direct 
endocardial cushion maturation and valve elongation, but is not required for initiation of 
EndMT [158]. In addition, TBX20 regulates Lef1, a key transcriptional mediator for WNT/β-
catenin signaling, in this developmental process [159] (Fig. 4B). As discussed in section 5.1 
BMP signaling induces the expression of aggf1 in ECs, which promotes β-catenin-mediated 
transcription of Nr2f2/CouptfII important for cardinal vein identity [85] (Fig. 4B). 
Finally, it has been described – although not yet in ECs - that the BMP signaling 
duration becomes prolonged when levels of canonical WNT signaling are high. This can be 
explained by the fact that WNT signaling inhibits GSK3 and thus prevents GSK3-mediated 
inhibitory linker phosphorylation of SMAD1 and SMAD4 [160, 161] (Fig. 4B). 
7.3. BMP and Hippo signaling 
The Hippo cascade is a critical pathway for mechanotransduction and the regulation of cell-
cell contacts; this pathway seems not to have a classical ligand-receptor interaction but to be 
activated by cell polarity, cell-cell contact, cellular stress and mechanotransduction (Fig. 4C). 
Activation of LATS1/2 (large tumor suppressor) kinases results in phosphorylation and 
cytoplasmic retention of amongst others YAP (yes-associated protein) and TAZ 
(transcriptional co-activator with a PDZ-binding domain). In the absence of Hippo signaling, 
YAP and TAZ act in the nucleus and regulate transcription via interaction with cognate 
transcription factors, like TEADs (reviewed in [162]). YAP mediates endothelial junctional 
stability and vascular remodeling via Angiopoietin 2 [163]. 
Recently, BMP-SMADs have also been implicated in Hippo crosstalk in ECs. BMP9 
has been shown to induce YAP1 nuclear localization in an Endoglin-dependent manner [164]. 
Furthermore, the YAP target genes CCN1 (cysteine-rich 61, CYR61) and CCN2, also known 
as connective tissue growth factor (CTGF), as well as the chemokine CCL2 (monocyte 
chemotactic protein 1, MCP-1) are regulated by BMP9 [164].  
It was recently shown in epithelial cells that SMAD1 linker phosphorylation 
mediates binding of YAP to this region resulting in full activation of SMAD-dependent 
transcription [165]. It is not known yet whether this will also occur in the endothelium. 
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YAP has recently been shown to regulate EndMT in endocardium [166]; given the 
pivotal role of BMP2 in this event it is tempting to speculate that Hippo and BMP pathways 
may cooperate in the process of atrioventricular valve formation as well.  
7.4. BMP and FGF signaling 
FGF signaling has been implicated in early vascular development. The FGF family consists of 
18 FGFs that activate via interaction with tyrosine kinase receptors intracellular RAS-MAPK, 
PI3K-Akt, PLC-γ and STAT intracellular signaling pathways [167]. Many of these pathways 
intersect with BMP elicited non-SMAD cascades. High levels of FGF signaling will also 
shorten the BMP signaling duration because of increased MAPK activity and MAPK-
mediated inhibitory linker phosphorylation of SMADs [160, 161], however this has not been 
described in ECs yet. Enhanced expression and activation of the FGF signaling pathway 
results in increased levels of BMPER, which has been described to dampen the BMP response 
and to promote angiogenesis [82, 168]. BMP was recently shown to induce FGFR1 and 2 in 
ECs [68]. 
7.5. BMP and VEGF signaling and the hypoxic environment 
BMP4, BMP7 and BMP9 repress VEGF expression [169, 170] (Fig. 4D). BMP9 also 
represses the expression of VEGFR2 and induces the expression of VEGFR1 [19, 47, 56], 
which is described as a receptor trap for VEGF, further supporting that BMPs decrease VEGF 
signaling in ECs (Fig. 4D). Interestingly, AVM formation in Eng or Alk1 loss-of-function is 
strongly potentiated by VEGF and reciprocally interference with the VEGF pathway has 
shown beneficial effects in the treatment of HHT [171, 172].  
Although hypoxia is not a classical signaling pathway, it is a major trigger for 
angiogenesis; hence we discuss here the consequences of hypoxia on expression of BMP 
signaling components. BMPs secreted under hypoxic conditions – remotely from the vessel - 
may diffuse and contribute in concert with other pro-angiogenic signals like VEGF in the 
activation of tip cells in nearby vessels; this may trigger activation of distinct receptor 
complexes and cascades than the circulatory BMPs that activate ECs at the luminal side. 
Several studies have reported that expression of BMP4 is induced by hypoxia [173-175] (Fig. 
4D). Hypoxia and ischemic reperfusion in intestinal epithelium causes upregulation of 
Bmp2/4 and Alk3 and Bmpr2 [176]. In cartilage and osteoblasts, hypoxia induced expression 
of Bmp2 is partially mediated through HIF1α induced ILK/mTOR/AKT pathways [177, 178]. 
Conversely, BMP9/SMAD1/5/8 mediated signaling induces expression of HIF1 in 
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mesenchymal stromal cells [179], while BMP2 downregulates HIF1 in GBM cells [180]. It 
remains whether similar regulations occur in ECs. 
8. Conclusions and perspectives
In this review we have zoomed in on recent discoveries on how BMP signaling co-regulates 
vascular biology and functions, and how impaired BMP signaling can underlie disease. One 
of the emerging trends is the pro-inflammatory and atheriogenic, remodeling role of BMP 
signaling in the vessel wall and the valvular endocardium, which seems tightly linked to the 
interpretation of mechanosensitive responses derived from blood flow. In addition to the 
crucial crosstalks of BMP signaling and Notch, WNT, or Hippo signaling cascades it becomes 
very clear that the BMP-pathway is a core signaling cascade in vascular cells. Exciting 
progress has also been made towards the development of agents for the treatment of vascular 
disorders.  
The recent studies have opened the door for several important unanswered questions 
with respect to BMP signaling within endothelial beds. We have listed a few of them:  
 What are the differences in ALK1-BMP9/10 signaling versus other branches of the
BMP signaling pathway? In other words what determines the specificity of the type-1
receptor signaling? Which roles play non-SMAD versus SMAD signaling in
explaining EC plasticity and heterogeneity?
 Are there specific targets and functions for SMAD1, SMAD5 and SMAD8? SMAD8
being linked to vascular disease suggests no redundancy in the adult vasculature.
 How widespread or scattered and dynamic is signaling in different vascular beds?
 What is the impact of miRNA or lncRNA mediated silencing of BMP signaling
components on vascular integrity of different vascular beds?
 Could somatic loss-of-heterozygosity of ALK1 or ENG trigger lesion development in
HHT or PAH patients, as was shown for CCM [181]?
 How can mutations in the same ACVRL1/BMPR2 pathway cause different diseases,
PAH versus HHT? Can we imagine similar therapeutically approach for these 2
diseases? How do mutations of BMPR2, ACVRL1 and ENG cause diseases that are
restricted to pulmonary circulation or liver, lungs, and brain, respectively [182]?
The many levels of modulation of the BMP signaling cascade (see also review by others in 
this issue) by e.g. the ECM, co-receptors, competition for the receptors or the SMADs 
between BMPs, endocytosis, post-translational modifications and degradation, or miRNAs all 
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contribute to the highly context-dependent physiological roles and activities of BMPs in 
different vascular beds. So does the intersection between BMP and other signaling cascades; 
and the formation of different receptor complexes with different ligand affinities. This 
complexity often confounds results obtained in cell culture experiments using different cell 
types and model organisms. A deeper understanding of the context-dependency and the 
different effects of BMP signaling on arteries, veins and lymphatic vessels, on capillary beds 
of different organs or on tip, stalk and phalanx ECs may give insight in vessel-type restricted 
disorders and lead to refinement of (anti)-angiogenic therapies. 
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Legends to Figures 
Throughout all figures, genes are italicized and in capitals, while proteins are in regular font 
irrespective whether data is obtained in human, mouse or zebrafish models.  See main text for 
further details, abbreviations and references.  
Figure 1. Schematic overview of BMP signaling in endothelial cells (ECs). BMP dimers 
signaling are triggered by ligand binding to heteromeric surface receptor complexes of 
specific type II and type I receptors. Different BMP subgroups can signal via different 
receptor complexes (black and dashed arrows correspond respectively to high and lower 
affinity receptors). The relative levels of type I and type II (mRNA) in ECs are represented, 
this however depends on the EC origin as ALK6 has been found highly expressed in 
HUVECs (asterisk) [18]. Ligand binding triggers activation of the type I receptors by the type 
II receptors. SMAD- and non-SMAD pathways can become activated. SMAD1/5/8 are the 
effectors of the BMP SMAD-pathway. Phosphorylated SMAD1/5/8 (pSMAD1/5/8) form 
heteromeric complexes with SMAD4 and translocate to the nucleus where they regulate target 
gene expression by interaction with other transcription factors (not illustrated). Non-SMAD 
pathways (depicted in blue) involve the activation of different kinases that can affect 
transcriptional regulation or non-transcriptional functions [183]. BMPs regulate many 
signaling components involved in EC signaling.  
Figure 2. BMP signaling and hemodynamics forces in the vasculature. BMPs and flow-
induced hemodynamic changes co-regulate the remodeling response of ECs. Blood flow 
increases ALK1 levels. Laminar shear stress (LSS) and oscillatory shear stress (OSS) affect 
intracellular SMAD1/5/8 signaling differentially and OSS upregulates ICAM-1 and VCAM-1 
in a BMP4-dependent manner. OSS induces synergistic interactions between BMP receptors 
and integrin (αvβ3) to activate SMAD1/5 through the Shc/FAK/ERK pathway, which leads to 
the activation of the Runx/mTOR/p70S6K pathway to regulate EC cycle. BMP-SMAD 
signaling induces Msx1 in arteries during ischemic reperfusion. MSX1 then induces through 
induction of ICAM-1 and VCAM-1 an inflammatory response and atheriogenic remodeling 
response.  BMP-SMAD signaling and the lack of tethering of β-catenin at the plasma 
membrane due to absence of the primary cilium cooperatively enhances the β-catenin-
mediated induction of Slug, which triggers EndMT and mineralization remodeling.  
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Figure 3. Defects associated with impaired BMP signaling in blood and lymphatic 
vasculature. The blood vasculature consists of a hierarchical network of arteries and 
arterioles (red), a capillary network, and venules and veins (blue). Blind-ending lymphatic 
capillaries (green) drain extravasated fluid and cells from the capillary bed into collecting 
vessels. The lymph fluid is further transported to lymph nodes and ducts, and back into the 
blood circulation. Peri-endothelial cells cover the ECs; VSMCs are associated with arteries 
and veins, whereas the capillaries in the capillary bed are covered only sparsely by pericytes 
(the difference in coverage is not indicated in the scheme). The collecting lymphatic vessels 
are covered by few VSMCs and these vessels contain valves that prevent backflow of lymph 
fluid. When BMP signaling is unbalanced in the vasculature, then this can result in different 
blood and lymphatic vessel defects. So far two diseases have been linked to impaired BMP 
signaling in human: pulmonary arterial hypertension (PAH, mutations in BMPR2, ACVRL1, 
SMAD8) characterized by aberrant vascular remodeling that can lead to obstruction of small 
arteries and hereditary hemorrhagic telangiectasia (HHT, mutations in ENG, ACVRL1, 
SMAD4, GDF2 (BMP9)) characterized by arteriovenous shunts, poor vessel coverage and 
hemorrhages. Cerebral cavernous malformation (CCM) has been associated to increased 
BMP6 signaling. Lymphatic defects (hyperproliferation, dilation, lack of valves, poor 
drainage) have so far only been observed in mouse and zebrafish models with impaired 
BMP2, BMP9, ALK1 and SMAD5 signaling. BMPs have also been associated with tumor 
angiogenesis. 
Figure 4. Intersections between BMP signaling cascades and other signaling pathways in 
endothelium. A. BMP and Notch signaling synergize and antagonize in ECs. BMP-SMAD 
signaling induces several genes independently of Notch-mediated signaling, also so-called 
Notch targets (1), but pSMAD1/5/8 and NICD, the Notch intracellular domain, can interact 
and can synergistically induce genes (2). HES and HEY are bHLH transcriptional repressors, 
while ID proteins are HLH factors that can dimerize with bHLH proteins. HES1 autorepresses 
its own transcription, this repression is released by the interaction between ID and HES1 (3), 
resulting in HES1 accumulation and HES1 mediated repression of Dll4 (4) and Vegfr2, which 
is important for stalk cell competence. When protein interactions of IDs shift towards HEY, 
then IDs is targeted for proteosomal degradation (5), this antagonism results in regained 
autorepression of HES1. pSMAD1/5/8 induced production of JAG1 dampens Notch signaling 
in the tip cell (6). Neuropilin 1 (NRP1), a tip cell determinant, has also been reported to be 
actively repressed by Notch-mediated signaling in the stalk cell.  B. BMP and WNT signaling 
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enforce each other in ECs. In brief, the absence of canonical WNT ligand-receptor binding, 
GSK3 mediates phosphorylation and destabilization of cytoplasmic β-catenin and activated 
BMP-SMADs.  When WNTs bind Frizzled-LRP receptors, then GSK3 activity is blocked 
resulting in stabilization of activated BMP-SMADs and β-catenin. In zebrafish, aggf1 is 
induced by BMP-SMAD signaling in veins, which on its turn enforce β-catenin/Tcf/Lef 
mediated induction of Nr2f2/CoupTFII. CoupTFII is an important regulator of venous and 
lymphatic identity. Also in the heart BMP signaling enforces WNT signaling because LEF1 
becomes enriched in endocardium through BMP-SMAD signaling induced production of 
TBX20. C. YAP and TAZ are Hippo effectors. The BMP9/Endoglin axis triggers nuclear 
localization of YAP, and co-regulates the YAP target genes Ccn1/Cyr61, Ccn2/Ctgf, as well 
as the chemokine Ccl2/Mcp-1 and subsequent cell matrix remodeling and local inflammatory 
responses. D. BMP signaling and hypoxia synergize in hypoxia sensitive processes. Hypoxia 
induces via HIF1α the induction of pro-angiogenic cues like Vegf but also of Bmp2 and -4. It 
is tempting to speculate that these BMPs can enhance angiogenic sprouting and migration in 
nearby vessels. HIF1α also induces expression of the BMP receptors Alk3 and BmpRII. 
Activation of the BMP-SMAD signaling cascade further boosts the HIF1α-mediated 
induction of hypoxia sensitive genes through the induction of Hif1, Ilk1 and Ets1 (172-173), 
but also down-regulates the VEGF signaling pathway.  
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